Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study will explore the combination of a stereotactic body radiation therapy (SBRT)
approach combined with one year of luteinizing hormone releasing hormone (LHRH) agonist for
older men with high risk prostate cancer, or men unwilling to undertake conventionally
fractionated therapy and three years of adjuvant hormone therapy.
The purpose of this study is to examine the safety of a shorter course of radiation treatment
combined wtih androgen deprivation therapy.